---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-005946"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T11:29:50.428125+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Palatin updates on PL9643 dry eye Phase 3 lead-in data and PL8177 UC data

## Summary
- PL9643 lead-in data from MELODY-1 Phase 3 shows excellent ocular tolerability and broad efficacy on dry eye signs/symptoms.
- PL8177 preclinical data in rat UC models reduces colonic damage; oral formulation delivers to colon without systemic absorption.
- Phase 2 study PL8177-205 for UC enrolling; interim and topline data expected in 2H2023.
- KOL webinar replay with Dr. Stouch, Ousler, Raizman available on Palatin website.

## SEC filing metadata
- accession: 0001654954-23-005946
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423005946/0001654954-23-005946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423005946/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-005946
- JSON: https://secwatch.observer/filing/0001654954-23-005946.json
- Plain text: https://secwatch.observer/filing/0001654954-23-005946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.